Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O Jr, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sepúlveda Sánchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Tannir NM, et al. Among authors: gandhi s. JAMA Oncol. 2022 Oct 1;8(10):1411-1418. doi: 10.1001/jamaoncol.2022.3511. JAMA Oncol. 2022. PMID: 36048457 Free PMC article.
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel P, Sweis RF, Bupathi M, Heath E, Goodman OB Jr, Hoimes CJ, Milowsky MI, Davis N, Kalebasty AR, Picus J, Shaffer D, Mao S, Adra N, Yorio J, Gandhi S, Grivas P, Siefker-Radtke A, Yang R, Latven L, Olson P, Chin CD, Der-Torossian H, Mortazavi A, Iyer G. Msaouel P, et al. Among authors: gandhi s. Eur Urol Oncol. 2024 Aug;7(4):933-943. doi: 10.1016/j.euo.2023.12.001. Epub 2023 Dec 16. Eur Urol Oncol. 2024. PMID: 38105142 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.
Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS. Wang ES, et al. Among authors: gandhi s. J Hematol Oncol. 2012 Nov 29;5:71. doi: 10.1186/1756-8722-5-71. J Hematol Oncol. 2012. PMID: 23190430 Free PMC article. Clinical Trial.
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
Williams H, Omer DM, Thompson HM, Lin ST, Verheij FS, Miranda J, Yuval JB, Buckley J, Marco MR, Qin LX, Dombroski DA, Kedar R, Oto A, Korngold E, Veniero JC, Gandhi S, Krishnaraj A, Jagtiani M, Ohanian K, Vu D, Hope TA, Lee S, Wasnik AP, Madhuripan N, Gollub MJ, Garcia-Aguilar J; OPRA Consortium. Williams H, et al. Among authors: gandhi s. Radiology. 2024 Sep;312(3):e232748. doi: 10.1148/radiol.232748. Radiology. 2024. PMID: 39225603 Clinical Trial.
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Falchook GS, Reeves J, Gandhi S, Spigel DR, Arrowsmith E, George DJ, Karlix J, Pouliot G, Hattersley MM, Gangl ET, James GD, Thompson J, Russell DL, Patel B, Kumar R, Lim E. Falchook GS, et al. Among authors: gandhi s. Cancer Immunol Immunother. 2024 Mar 2;73(4):72. doi: 10.1007/s00262-024-03640-6. Cancer Immunol Immunother. 2024. PMID: 38430405 Free PMC article. Clinical Trial.
Emergence of SARS-CoV-2 subgenomic RNAs that enhance viral fitness and immune evasion.
Mears HV, Young GR, Sanderson T, Harvey R, Barrett-Rodger J, Penn R, Cowton V, Furnon W, De Lorenzo G, Crawford M, Snell DM, Fowler AS, Chakrabarti AM, Hussain S, Gilbride C, Emmott E, Finsterbusch K, Luptak J, Peacock TP, Nicod J, Patel AH, Palmarini M, Wall E, Williams B, Gandhi S, Swanton C, Bauer DLV. Mears HV, et al. Among authors: gandhi s. PLoS Biol. 2025 Jan 21;23(1):e3002982. doi: 10.1371/journal.pbio.3002982. Online ahead of print. PLoS Biol. 2025. PMID: 39836705 Free article.
Human relevant frontiers in drug safety and efficacy.
Mahadik K, Visala A, Chatterjee N, Pahuja M, Mehta V, Dhurde T, Nayak G, Ahmed T, Devireddy N, Krishnan A, Viswanathan K, Gandhi S, Mehta G, Karmwar P, Paleja B, Mohanty S, Parvatam S, Pallela R, Rao M. Mahadik K, et al. Among authors: gandhi s. ALTEX. 2025;42(1):146-151. doi: 10.14573/altex.2411131. ALTEX. 2025. PMID: 39817836 Free article. No abstract available.
2,186 results